On Air Now

Listen

Listen Live Now » 94.7 FM Central Wisconsin 102.9 FM Wausau, WI

Weather

Current Conditions(Wausau,WI 54403)

More Weather »
73° Feels Like: 73°
Wind: NW 8 mph Past 24 hrs - Precip: 0”
Current Radar for Zip

Tonight

Partly Cloudy 54°

Tomorrow

PM Thunderstorms 78°

Tues Night

Thunderstorms Early 52°

Alerts

GSK's Tafinlar named as FDA breakthrough therapy for lung cancer

The logo of GlaxoSmithKline (GSK) is seen on its office building in Shanghai July 12, 2013. REUTERS/Aly Song
The logo of GlaxoSmithKline (GSK) is seen on its office building in Shanghai July 12, 2013. REUTERS/Aly Song

LONDON (Reuters) - British pharmaceutical company GlaxoSmithKline said its Tafinlar cancer treatment had been given FDA breakthrough therapy designation for lung cancer, meaning the drug will be fast-tracked within the U.S. regulatory system.

GSK said that Tafinlar, also known as dabrafenib, was designated an FDA breakthrough therapy on Monday following interim results from an ongoing Phase II study.

Tafinlar is already approved for melanoma, the deadliest form of skin cancer.

(Reporting by Sarah Young, Editing by Paul Sandle)

Comments